Swanbridge Capital

AI Verified

Location

Netherlands


Investor type

Venture Capital


Current investment status

00 00 00


Website

http://swanbridgecapital.nl/


Linkedin

00 00 00


Submission link

00 00 00


Company address

16 Marconistraat, 3029 AK Rotterdam, South Holland, Netherlands


Founding year

2016


Twitter

00 00 00


Facebook

00 00 00

Criteria Requirements Match
Regions Northern Europe, Western Europe
00
Countries
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Sector
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Impact Area
00 00 00
Stage Seed, Series A, Bridge, Pre-Seed
00
Ticket size
00 00 00
-
00 00 00
USD
00
Monetization model
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Product readiness
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Client types
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Min. revenue
00 00 00
USD
00
Other
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
-

Unlock Free Premium Insights

Discover how well you match with this investor and reach out on the Raise Better platform.

  • Advanced matching algorithm
  • Detailed compatibility scores
  • Priority investor access
Create Free Account

Company description

Swanbridge Capital operates as a specialized venture capital fund headquartered in Rotterdam, focusing exclusively on early-stage healthcare innovations. The firm strategically directs its investments toward promising startups developing novel therapeutics, cutting-edge diagnostic technologies, and innovative medical devices that address significant unmet medical needs. With a dedicated team of life science experts and investment professionals, Swanbridge has established itself as a key player in the European biotech investment landscape since its founding.

What distinguishes Swanbridge from many other venture capital entities is its willingness to engage with companies at the pre-proof-of-concept stage, a phase many traditional investors consider too risky. This early involvement allows the fund to support groundbreaking technologies when they most need capital infusion, often before clinical validation or regulatory approval processes have been completed. Their investment thesis centers on identifying scientifically sound innovations with significant commercial potential that could transform patient care pathways.

The fund employs a hands-on investment approach, going well beyond merely providing financial resources. Swanbridge's partners actively participate in strategic decision-making, business development initiatives, and operational improvements within their portfolio companies. This collaborative model includes offering expertise in clinical development strategies, regulatory navigation, intellectual property management, and facilitating connections with potential pharmaceutical partners. Their team typically takes board positions and works closely with founding scientists and management teams to accelerate development timelines and enhance company value.

Swanbridge's portfolio reflects its commitment to advancing healthcare innovation across multiple therapeutic areas, including oncology, neurology, and rare diseases. The fund typically makes initial investments ranging from early seed rounds through Series A financing, with capital reserved for follow-on investments in promising portfolio companies. Their investment strategy emphasizes technologies with clear differentiation, strong intellectual property protection, and addressing substantial market opportunities. For entrepreneurs seeking not just financial backing but also strategic guidance and industry connections, Swanbridge Capital positions itself as a value-added partner throughout the challenging journey from scientific discovery to commercial success.

Highlights

Venture capital fund specializing in early-stage medtech
Offers hands-on involvement beyond financial investment

Ready to raise better?

Create your Free Account!

Frequently asked questions

Where is Swanbridge Capital located?

Swanbridge Capital maintains its global headquarters in Netherlands, serving as the strategic center for its operations. The company's primary corporate offices are located at 16 Marconistraat, 3029 AK Rotterdam, South Holland, Netherlands.

What investment stages Swanbridge Capital focuses on?

Swanbridge Capital focuses its investment activities on companies operating in the following stages: Seed, Series A, Bridge, Pre-Seed. Swanbridge Capital provides strategic capital and expertise to support promising businesses at these critical phases of development.

Where does Swanbridge Capital invest?

Swanbridge Capital maintains a strategic global investment presence, actively seeking opportunities across the following key regions: Northern Europe, Western Europe.

When was Swanbridge Capital founded?

Swanbridge Capital was established in 2016, marking the beginning of its journey as an investment firm.

What kind of investment firm is Swanbridge Capital?

Swanbridge Capital is the following type of investment firm: Venture Capital. The organization provides capital and strategic support to entrepreneurs and growing companies.